Section Arrow
IMAB.NASDAQ
- I-MAB
Quotes are at least 15-min delayed:2024/05/31 20:48 EDT
Last
 1.66
-0.08 (-4.60%)
Day High 
1.75 
Prev. Close
1.74 
1-M High
1.91 
Volume 
159.22K 
Bid
1.67
Ask
1.67
Day Low
1.66 
Open
1.74 
1-M Low
1.7275 
Market Cap 
140.74M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.75 
20-SMA 1.78 
50-SMA 1.8 
52-W High 3.38 
52-W Low 1.16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-17.62/-1.75
Enterprise Value
222.75M
Balance Sheet
Book Value Per Share
2.98
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
27.64M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.5285-0.0308-5.51%-- 
SMMTSummit Therapeutics8.685-2.235-20.47%28.74PE
KTRAKintara Therapeutics0.3166-0.0004-0.13%-- 
SRPTSarepta Therapeutics129.86+5.41+4.35%289.42PE
NVAXNovavax15.03-0.22-1.44%-- 
Quotes are at least 15-min delayed:2024/05/31 20:48 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.